|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent No. 9,763,933
U.S. Patent No. 9,763,933, granted on September 19, 2017, to Bristol-Myers Squibb Company, covers methods for treating patients with cancer using a programmed cell death protein 1 (PD-1) inhibitor. The patent specifically addresses the use of nivolumab in combination with other anti-cancer agents, including chemotherapy. This patent is a key component of Bristol-Myers Squibb's intellectual property strategy for its immuno-oncology portfolio.
What is the Primary Therapeutic Focus of Patent 9,763,933?
The patent focuses on the treatment of cancer by enhancing the body's immune response to tumor cells. It specifically details methods involving the administration of nivolumab, a human monoclonal antibody that blocks the PD-1 pathway. This blockade re-enables T cells to recognize and attack cancer cells more effectively.
- Target Pathway: Programmed cell death protein 1 (PD-1)
- Active Agent: Nivolumab (Opdivo)
- Disease Area: Cancer
What Specific Claims Does Patent 9,763,933 Protect?
Patent 9,763,933 contains several claims related to methods of treating cancer. The core claims involve the sequential or concurrent administration of nivolumab with other therapeutic agents.
- Claim 1: A method of treating a subject with cancer, comprising: administering an anti-PD-1 antibody to the subject; and administering a chemotherapeutic agent to the subject.
- Claim 2: The method of claim 1, wherein the anti-PD-1 antibody is nivolumab.
- Claim 3: The method of claim 2, wherein nivolumab is administered prior to the chemotherapeutic agent.
- Claim 4: The method of claim 2, wherein nivolumab is administered concurrently with the chemotherapeutic agent.
- Claim 5: The method of claim 2, wherein the chemotherapeutic agent is selected from the group consisting of platinum-based chemotherapy, taxane chemotherapy, and gemcitabine.
- Claim 6: The method of claim 2, wherein the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, and malignant pleural mesothelioma.
These claims aim to protect specific treatment regimens, thereby broadening the commercial exclusivity for nivolumab in certain oncology indications when used in combination therapies. The patent's language emphasizes the method of treatment rather than the compound itself, which is crucial for patenting new uses of existing drugs.
How Does Patent 9,763,933 Define Combination Therapies?
The patent defines combination therapies through the administration of an anti-PD-1 antibody, specifically nivolumab, alongside other anti-cancer treatments. The critical aspect is the sequence and timing of these administrations.
- Sequential Administration: The patent covers scenarios where nivolumab is given before or after other agents. This allows for flexibility in clinical practice and captures different therapeutic strategies.
- Concurrent Administration: The patent also protects the simultaneous administration of nivolumab with other drugs, such as chemotherapy.
- Specific Agents: While the claims mention general categories like "chemotherapeutic agent," they also provide specific examples, such as platinum-based chemotherapy, taxane chemotherapy, and gemcitabine.
The detailed definition of these combinations is designed to prevent competitors from using similar treatment protocols without infringing on Bristol-Myers Squibb's patent rights.
What are the Key Indications Covered by the Patent?
The patent explicitly lists several cancer types for which the described treatment methods are applicable. This broadens the scope of protection beyond a single cancer indication.
- Non-Small Cell Lung Cancer (NSCLC): This is a major focus, given the high prevalence and the known efficacy of PD-1 inhibitors in this disease.
- Small Cell Lung Cancer (SCLC): Another significant lung cancer subtype.
- Malignant Pleural Mesothelioma: A rare but aggressive cancer often associated with asbestos exposure.
The inclusion of these specific indications signifies an intent to secure market exclusivity for nivolumab-based combination treatments across multiple high-impact cancer types.
What is the Patent Landscape for Nivolumab and PD-1 Inhibitors?
The patent landscape for nivolumab and other PD-1 inhibitors is highly competitive and complex, characterized by extensive patent filings by multiple pharmaceutical companies. Bristol-Myers Squibb holds a significant portfolio of patents covering nivolumab, its manufacturing, formulations, and methods of use.
Key Players in the PD-1 Inhibitor Landscape:
- Bristol-Myers Squibb: Dominant with nivolumab (Opdivo).
- Merck & Co.: Key competitor with pembrolizumab (Keytruda).
- Roche: Has atezolizumab (Tecentriq), a PD-L1 inhibitor.
- AstraZeneca: Has durvalumab (Imfinzi), a PD-L1 inhibitor.
- Pfizer/Merck KGaA: Have avelumab (Bavencio), a PD-L1 inhibitor.
The patent landscape for PD-1 inhibitors includes:
- Composition of Matter Patents: These are the strongest patents, covering the drug molecule itself. Nivolumab's core composition of matter patents have expired or are nearing expiration, increasing the risk of biosimilar competition.
- Method of Treatment Patents: Like Patent 9,763,933, these patents protect specific uses or combinations of the drug. They are crucial for extending market exclusivity beyond the expiration of composition of matter patents.
- Formulation Patents: Cover specific ways the drug is delivered (e.g., oral, injectable, specific stabilizers).
- Manufacturing Process Patents: Protect the methods used to synthesize or purify the drug.
Impact on Competition:
The existence of patents like 9,763,933 creates significant barriers to entry for competitors. Companies seeking to market generic or biosimilar versions of nivolumab must navigate this complex patent landscape, identifying patents that are either expired, invalid, or not infringed by their proposed product. Litigation over patent validity and infringement is common in this space.
What is the Significance of Method of Treatment Patents in the Immuno-Oncology Era?
Method of treatment patents are increasingly vital in the pharmaceutical industry, particularly for blockbuster drugs like nivolumab. As the original composition of matter patents approach expiration, these patents provide a secondary layer of protection, allowing companies to extend market exclusivity.
- Extending Exclusivity: They protect novel uses, combinations, dosages, or patient populations, even after the core drug molecule patent has expired.
- Defending Market Share: Companies can use these patents to prevent generic or biosimilar competitors from using specific, highly effective treatment regimens.
- Strategic Differentiation: They allow companies to carve out distinct therapeutic niches and position their drugs in specific clinical settings.
For Bristol-Myers Squibb, patents like 9,763,933 are essential for defending its market leadership in PD-1 inhibition against emerging biosimilar threats and competitive immuno-oncology agents.
How Does Patent 9,763,933 Relate to Regulatory Approval Pathways?
Patent 9,763,933 is directly relevant to the U.S. Food and Drug Administration's (FDA) regulatory approval pathways, specifically concerning the Hatch-Waxman Act.
- Patent Listing in Orange Book: Bristol-Myers Squibb lists this patent in the FDA's "Approved Drug Products with Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). This official listing signifies that the patent claims are relevant to the approved uses of the drug.
- Patent Certifications by Generic/Biosimilar Applicants: When a generic or biosimilar company seeks approval, it must submit a Paragraph IV certification, stating that its proposed product does not infringe on any listed patents or that the listed patents are invalid.
- Patent Litigation: The existence of a listed patent like 9,763,933 can trigger patent litigation if a generic or biosimilar applicant files a Paragraph IV certification. The patent holder has a period of exclusivity (180-day exclusivity for the first filer) if they win the litigation.
The strength and validity of Patent 9,763,933 are therefore critical for Bristol-Myers Squibb to maintain its market exclusivity for specific combination therapies involving nivolumab.
What is the Expected Lifespan and Impact of Patent 9,763,933?
Patent 9,763,933 was granted on September 19, 2017. Under U.S. patent law, utility patents typically have a term of 20 years from the filing date, subject to potential extensions. The filing date for this patent was October 1, 2015.
- Estimated Expiration: Based on a standard 20-year term from the filing date, the patent is expected to expire around October 1, 2035.
- Potential for Patent Term Adjustment (PTA): The patent may be eligible for Patent Term Adjustment (PTA) if there were delays in its prosecution at the USPTO. This could extend the expiration date.
- Impact on Competition: Until its expiration, Patent 9,763,933 protects Bristol-Myers Squibb's rights to specific combination treatment methods involving nivolumab. Competitors wishing to market generic or biosimilar nivolumab would need to avoid these patented methods. The expiration of this patent would open up opportunities for competitors to utilize these specific combination therapies.
The continued enforceability of this patent is a significant factor in the commercial strategy for Opdivo and its related combination products.
How Does Patent 9,763,933 Position Bristol-Myers Squibb in the Market?
Patent 9,763,933 solidifies Bristol-Myers Squibb's market position by:
- Protecting Key Combination Therapies: It safeguards its intellectual property for specific, potentially high-value, combination treatment regimens that have demonstrated clinical efficacy.
- Deterring Biosimilar Competition: By protecting specific methods of use, it makes it more challenging for biosimilar manufacturers to enter the market with the full spectrum of approved treatments for nivolumab.
- Supporting Further R&D Investment: The assurance of extended market exclusivity for certain applications encourages continued investment in research and development of new combinations and indications for nivolumab.
The patent is a strategic asset that contributes to Opdivo's long-term commercial viability and Bristol-Myers Squibb's leadership in the immuno-oncology field.
Key Takeaways
- U.S. Patent No. 9,763,933 protects methods of treating cancer using nivolumab in combination with chemotherapy.
- The patent's claims cover sequential and concurrent administration of nivolumab with specific chemotherapeutic agents for indications including NSCLC, SCLC, and malignant pleural mesothelioma.
- This patent is a critical "method of treatment" patent, essential for extending market exclusivity for nivolumab beyond the expiration of its composition of matter patents.
- It is listed in the FDA's Orange Book, directly impacting regulatory pathways for generic and biosimilar applicants and potentially triggering patent litigation.
- The patent is expected to expire around October 1, 2035, and its enforceability is vital for Bristol-Myers Squibb's competitive strategy in the immuno-oncology market.
Frequently Asked Questions
-
What is the primary active pharmaceutical ingredient (API) protected by patent 9,763,933?
The patent primarily protects methods of using nivolumab, a human monoclonal antibody targeting PD-1.
-
Does patent 9,763,933 cover the drug nivolumab itself?
No, this patent covers methods of treatment using nivolumab, not the composition of matter of nivolumab itself.
-
What specific cancers are mentioned in the claims of patent 9,763,933?
The patent specifically mentions non-small cell lung cancer, small cell lung cancer, and malignant pleural mesothelioma.
-
Can a competitor use nivolumab if they do not infringe on the method claims in patent 9,763,933?
A competitor could theoretically use nivolumab if they avoid the specific combination treatment methods claimed in patent 9,763,933, provided they have independent regulatory approval and do not infringe on other valid patents.
-
What is the expected expiration date for U.S. Patent No. 9,763,933?
The patent was filed on October 1, 2015, and is expected to expire around October 1, 2035, subject to potential Patent Term Adjustment.
Citations
[1] Bristol-Myers Squibb Company. (2017). Method of treating cancer. U.S. Patent 9,763,933. Retrieved from USPTO Patent Full-Text and Image Database
More… ↓
⤷ Start Trial
|
